Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Citigroup Inc.

Citigroup Inc. increased its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 30.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 591,910 shares of the company’s stock after acquiring an additional 138,378 shares during the period. Citigroup Inc. owned about 0.15% of Moderna worth $39,557,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Ashton Thomas Private Wealth LLC purchased a new position in shares of Moderna in the 2nd quarter valued at about $26,000. Family Firm Inc. purchased a new stake in shares of Moderna in the second quarter valued at approximately $33,000. Bank & Trust Co acquired a new position in shares of Moderna during the 2nd quarter worth approximately $36,000. Hanseatic Management Services Inc. purchased a new position in shares of Moderna during the 2nd quarter valued at approximately $48,000. Finally, Plato Investment Management Ltd grew its stake in Moderna by 230.4% in the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock valued at $49,000 after acquiring an additional 288 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Moderna

In other Moderna news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. This represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders have sold 2,930 shares of company stock worth $217,170. 15.70% of the stock is currently owned by insiders.

Moderna Price Performance

MRNA stock opened at $41.11 on Monday. Moderna, Inc. has a 52-week low of $35.80 and a 52-week high of $170.47. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The stock has a market cap of $15.82 billion, a price-to-earnings ratio of -7.06 and a beta of 1.69. The business has a fifty day moving average of $54.96 and a two-hundred day moving average of $93.90.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. Moderna’s revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.39) EPS. As a group, research analysts anticipate that Moderna, Inc. will post -9.44 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have issued reports on MRNA. UBS Group decreased their price objective on shares of Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. Oppenheimer cut Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th. Jefferies Financial Group reduced their target price on Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a report on Tuesday, October 15th. Sanford C. Bernstein assumed coverage on Moderna in a research note on Thursday, October 17th. They issued a “market perform” rating and a $55.00 price target on the stock. Finally, HSBC raised Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research note on Monday, November 18th. Three investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $84.00.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.